靶向抗HSV-1的siRNA研究进展

Research Progress of siRNA Targeting Against HSV-1

单纯疱疹病毒1型(herpes simplex virus type 1,HSV-1)是一种能够在各类人群中携带和传播并能引起包括口唇疱疹、荚膜炎、角膜炎和病毒性脑炎等疾病的重要病原体。虽然已有多种类型的HSV-1疫苗处于研发的不同阶段,但仍没有商业化的疫苗上市销售。临床上使用的特异性抗HSV-1药物如阿昔洛韦、伐昔洛韦和喷昔洛韦等也面临严重的抗药性威胁,开发新的特异性抗HSV-1药物是当前所面临的主要任务之一。siRNA是一种长度为20~25核苷酸的双链RNA,通过在转录后水平上沉默基因表达发挥干扰作用。siRNA作为一种新的、有潜力的抗病毒药物备受关注,发展也较为迅速。综述近年来siRNA在抗HSV-1方面的研究进展,包括靶向HSV-1关键基因和HSV-1互作的宿主细胞基因的siRNA设计、递送和靶向策略。

HSV-1 is an important pathogen that can be carried and transmitted in various populations and can cause diseases including herpes labialis,capsulatus,keratitis and viral encephalitis.Although there are several types of HSV-1 vaccines in various stages of development,there is still no commercially available vaccine on the market.The specific anti-HSV-1 drugs used in clinical practice,such as acyclovir,valaciclovir and peniclovir,are also facing the serious threat of resistance.The development of new specific anti-HSV-1 drugs is one of the main tasks currently faced.siRNA is a double-stranded RNA with a length of 20-25 nucleotides that plays an interfering role by silencing gene expression at the post-transcriptional level.As a new and potential antiviral drug,siRNA has attracted much attention and developed rapidly.In this paper,we review the recent progress of siRNA in anti-HSV-1 research,including the design,delivery and targeting strategies of siRNA targeting key HSV-1 genes and HSV-1 interacting host cell genes.